26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy

Ever since the ubiquitin proteasome system was characterized, efforts have been made to manipulate its function to abrogate the progression of cancer. As a result, the anti-cancer drugs bortezomib, carfilzomib, and ixazomib targeting the 26S proteasome were developed to treat multiple myeloma, mantl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio, Andres J., Bencomo-Alvarez, Alfonso E., Young, James E., Velazquez, Vanessa V., Lara, Joshua J., Gonzalez, Mayra A., Eiring, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472613/
https://www.ncbi.nlm.nih.gov/pubmed/34572038
http://dx.doi.org/10.3390/cells10092390